Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Radiotherapy for the treatment of malignant pleural mesothelioma.
The Lancet ( IF 98.4 ) Pub Date : 2017-09-01 , DOI: 10.1016/s1470-2045(17)30459-x Marc de Perrot 1 , Licun Wu 2 , Matthew Wu 2 , B C John Cho 3
The Lancet ( IF 98.4 ) Pub Date : 2017-09-01 , DOI: 10.1016/s1470-2045(17)30459-x Marc de Perrot 1 , Licun Wu 2 , Matthew Wu 2 , B C John Cho 3
Affiliation
|
Malignant pleural mesothelioma is an aggressive disease that continues to be associated with poor outcomes. Although, traditionally this disease is considered to be resistant to radiotherapy, more recent evidence suggests that radiotherapy can produce positive outcomes. Over the past 15 years, the development of new, highly conformal radiotherapy techniques, such as intensity-modulated radiation therapy (IMRT), has enabled investigators to optimise the delivery of high-dose radiotherapy to the whole of the hemithorax. Prospective single-arm trials have shown that the median survival of patients who have completed high-dose hemithoracic radiotherapy after extrapleural pneumonectomy could reach 23·9-39·4 months independent of the chemotherapeutic response, suggesting that IMRT could potentially have an intrinsic benefit to this subset of patients. These observations have led to a change in practice, with the introduction of adjuvant pleural IMRT after pleurectomy-decortication and the development of induction-accelerated hemithoracic IMRT followed by extrapleural pneumonectomy. This Review focuses on recent observations on the role of radiotherapy in the treatment of malignant pleural mesothelioma, with particular emphasis on the results of clinical trials that evaluate the role of high-dose hemithoracic radiotherapy.
中文翻译：
放射治疗恶性胸膜间皮瘤。
恶性胸膜间皮瘤是一种侵袭性疾病，继续与不良预后相关。尽管传统上认为这种疾病对放疗有抵抗力，但最近的证据表明放疗可以产生积极的结果。在过去的15年中，诸如强度调制放射疗法（IMRT）等新的高度保形放射疗法的发展使研究人员能够优化向整个半胸腔的高剂量放射疗法的递送。前瞻性单臂试验表明，胸膜外肺切除术后完成大剂量半胸腔放疗的患者的中位生存期可达到23·9-39·4个月，而与化疗反应无关，这表明IMRT可能对这部分患者。这些观察结果导致了实践上的变化，在胸膜切除术脱皮后引入了辅助性胸膜IMRT，并发展了诱导加速型半胸腔IMRT，随后进行了胸膜外肺切除术。这篇综述集中在放射治疗在恶性胸膜间皮瘤治疗中的作用的最新观察，特别是评估大剂量半胸腔放疗作用的临床试验的结果。
更新日期：2017-09-04
中文翻译：
放射治疗恶性胸膜间皮瘤。
恶性胸膜间皮瘤是一种侵袭性疾病，继续与不良预后相关。尽管传统上认为这种疾病对放疗有抵抗力，但最近的证据表明放疗可以产生积极的结果。在过去的15年中，诸如强度调制放射疗法（IMRT）等新的高度保形放射疗法的发展使研究人员能够优化向整个半胸腔的高剂量放射疗法的递送。前瞻性单臂试验表明，胸膜外肺切除术后完成大剂量半胸腔放疗的患者的中位生存期可达到23·9-39·4个月，而与化疗反应无关，这表明IMRT可能对这部分患者。这些观察结果导致了实践上的变化，在胸膜切除术脱皮后引入了辅助性胸膜IMRT，并发展了诱导加速型半胸腔IMRT，随后进行了胸膜外肺切除术。这篇综述集中在放射治疗在恶性胸膜间皮瘤治疗中的作用的最新观察，特别是评估大剂量半胸腔放疗作用的临床试验的结果。
京公网安备 11010802027423号